EPS for iCAD Inc (ICAD) Expected At $-0.17

July 17, 2017 - By Adrian Mccoy

 EPS for iCAD Inc (ICAD) Expected At $ 0.17

Analysts await iCAD Inc (NASDAQ:ICAD) to report earnings on July, 26. They expect $-0.17 earnings per share, down 88.89 % or $0.08 from last year’s $-0.09 per share. After $-0.18 actual earnings per share reported by iCAD Inc for the previous quarter, Wall Street now forecasts -5.56 % EPS growth. The stock increased 1.26% or $0.05 on July 17, reaching $4.01. About 28,090 shares traded. iCAD Inc (NASDAQ:ICAD) has declined 14.66% since July 18, 2016 and is downtrending. It has underperformed by 31.36% the S&P500.

iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The company has market cap of $67.54 million. The Firm provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It currently has negative earnings. It operates in two divisions: Cancer Detection and Cancer Therapy (Therapy).

More notable recent iCAD Inc (NASDAQ:ICAD) news were published by: Seekingalpha.com which released: “iCAD’s (ICAD) CEO Ken Ferry on Q1 2017 Results – Earnings Call Transcript” on May 03, 2017, also Marketwatch.com with their article: “4.02” published on November 01, 2009, Prnewswire.com published: “iCAD Announces Breakthrough Technology For Use With Digital Breast …” on March 02, 2016. More interesting news about iCAD Inc (NASDAQ:ICAD) were released by: Prnewswire.com and their article: “iCAD Announces Increased Adoption Of iReveal® Automated Breast Density …” published on May 23, 2016 as well as Quotes.Wsj.com‘s news article titled: “icad Inc.” with publication date: February 13, 2011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.